Lexicon Pharma (LXRX) Reports In-Line Q3 EPS
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $2.55 --0%
EPS Growth %: -600.0%
Financial Fact:
Other income (expense), net: 564K
Today's EPS Names:
DTGI, OCCI, MAYS, More
EPS Growth %: -600.0%
Financial Fact:
Other income (expense), net: 564K
Today's EPS Names:
DTGI, OCCI, MAYS, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q3 EPS of ($0.21), in-line with the analyst estimate of ($0.21). Revenue for the quarter came in at $160 thousand versus the consensus estimate of $2.06 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morgan Stanley continues to recommend exposure to the broadening theme
- MetLife estimates Q2 2026 variable investment income below annual pace
- KLA Corporation (KLAC) PT Raised to $325 at Cantor Fitzgerald: Limited EPS Upside
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
